- The Publication of 10-Year Follow-Up Test Results on the First CYPHER(R) Sirolimus-Eluting Coronary Stent Patient Reveal the Stent’s Outstanding Efficacy and Safety Cordis Corporation, a worldwide leader in >> more Angiography >>
Archive for August, 2010
CORDIS Announces Results of Ten-Year CYPHER(R) Sirolimus-Eluting Coronary Stent – Earthtimes
Tuesday, August 31st, 2010Toshiba Installs 1,000th MR System Worldwide – Medical News Today
Tuesday, August 31st, 2010Diagnostic imaging leader Toshiba America Medical Systems, Inc. has installed its 1,000th MR system worldwide. Kosair Children’s Medical Center – Brownsboro, the only pediatric outpatient facility of its type >> Angiography >>
CORDIS Announces Results of Ten-Year CYPHER(R) Sirolimus-Eluting Coronary Stent – Earthtimes
Tuesday, August 31st, 2010- The Publication of 10-Year Follow-Up Test Results on the First CYPHER(R) Sirolimus-Eluting Coronary Stent Patient Reveal the Stent’s Outstanding Efficacy and Safety Cordis Corporation, a worldwide leader in >> Angiography >>
Latest Results from EINSTEIN Program Presented at European Society of Cardiology … – Daily Finance
Tuesday, August 31st, 2010Latest Results from EINSTEIN Program Presented at European Society of Cardiology … – Daily Finance
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), announced today that the investigational, oral anticoagulant rivaroxaban successfully demonstrated non-inferiority compared to the …
Latest Results from EINSTEIN Program Presented at European Society of Cardiology … – Daily Finance
Tuesday, August 31st, 2010Latest Results from EINSTEIN Program Presented at European Society of Cardiology … – Daily Finance
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), announced today that the investigational, oral anticoagulant rivaroxaban successfully demonstrated non-inferiority compared to the …
Latest Results from EINSTEIN Program Presented at European Society of Cardiology … – Daily Finance
Tuesday, August 31st, 2010Latest Results from EINSTEIN Program Presented at European Society of Cardiology … – Daily Finance
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), announced today that the investigational, oral anticoagulant rivaroxaban successfully demonstrated non-inferiority compared to the …